ClinicalTrials.gg
Active, not recruitingNCT06175338Updated Sep 19, 2024

Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis

A Phase 1 interventional study of Rituximab and MabThera® in Rheumatoid Arthritis, sponsored by Mabscale, LLC. Active, not recruiting at 12 sites in Russian Federation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Mabscale, LLC · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as active, not recruiting.
  • Registered 5 months after the study started (first participant enrolled Jun 2023, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
25th of 63
208 · median 159
Started
2023
the only one that year
Phase 1
6 of 63
none open now
Registered
60th of 63
by date

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 25th largest by enrollment, is the only one that started in 2023, is one of 6 in phase 1, and was the 60th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

A randomised, double blind, parallel group, multicentre study to compare the pharmacokinetics, pharmacodynamics, immunogenicity and safety of Rituximab (Mabscale LLC, Russia) versus MabThera® in patients with rheumatoid arthritis.

Read the detailed description

RIT-1/01092021 is a double-blind randomized, parallel group, multicenter clinical trial comparing pharmacokinetics, pharmacodynamics, immunogenicity and safety of Rituximab (Mabscale LLC, Russia) and MabThera® in adult patients with moderate or severe rheumatoid arthritis with insufficient response to treatment tumor necrosis factor (TNF-α) inhibitors receiving background treatment with methotrexate. The purpose of the study is to demonstrate equivalence of pharmacokinetics, pharmacodynamics, immunogenicity and safety of Rituximab (Mabscale LLC, Russia) and MabThera®. The study will take place across approximately 30 study sites in Russia in order to randomize 208 patients. Rituximab is a monoclonal antibody currently being developed by Mabscale LLC, as a proposed biosimilar to MabThera®, which is approved as treatment in case of insufficient response or toxicity to treatment tumor necrosis factor (TNF-α) inhibitors receiving background treatment with methotrexate. This randomized equivalence study is designed to meet the regulatory requirement for approval of a biosimilar product.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female 18-65 y.o. with body weight 50-120 kg
  • Patients with active rheumatoid arthritis with disease duration minimum 6 months prior to screening visit per ACR/EULAR 2019 criteria classification.
  • Moderate or severe active course of rheumatoid arthritis, which is defined as the fulfillment of all of the following conditions:

    • ≥6 tender joints (based on a score of 68 joints) at screening and baseline; And
    • ≥6 swollen joints (based on a score of 66 joints) at screening and at baseline; And
    • level of C-reactive protein is not less than 10 mg/l or ESR is not less than 28 mm/hour at screening.
  • Positive result of the analysis for antibodies to cyclic citrullinated peptide (≥10 units/ml) and / or the presence of rheumatoid factor (≥ 20 units/ml) at screening (see section).
  • Received treatment for RA and experienced an inadequate response or intolerance to treatment with at least 1 anti-TNF alpha therapy;
  • Must have received MTX for a minimum of 12 weeks, with the last 4 weeks, prior to screening at a stable dose 10-25 mg/week;

Exclusion criteria

Exclusion Criteria:

  • according to the MabThera SmPC and every serious coexisting diseases which, in the Investigator's opinion, would preclude subject participation
  • History of current rheumatic disease other than RA and current inflammatory joint disease other than RA
  • Positive tests for , surface antigen (HBsAg) Anti-HBc antibody, antibody
  • Prior treatment with rituximab, other anti-CD20 mAb
  • Pregnancy or lactation or women planning to get pregnant during the course of the study and/or within 12 months post last study drug infusion
  • COVID prior 8 weeks prior to Screening visit or other acute systemic infection within 4 weeks prior to Day 1
  • Allergic reaction or intolerance to rituximab, MabionCD20 or any of their components
  • Severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or previous treatment of any lymphocyte-depleting therapies
  • Confirmed current active tuberculosis (TB).
  • Any significant cardiac disease
  • History of a severe allergic reaction or anaphylactic reaction to a biological agent or history of to any component of the study drug including known hypersensitivity or allergy to a murine product.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    Rituximab (manufactured by Mabscale, LLC)

    Eligible subjects (104 patients) will receive Rituximab 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml) twice: on Visit 1 and 5. The following visits are the visits of safety and PK, PD and immunogenicity and also preliminary effectiveness). Patients will also receive background treatment Methotrexate+ Folic acid.

    Drug: Rituximab

  • Active comparator
    MabThera®

    Eligible subjects (104 patients) will receive MabThera® 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml) twice: on Visit 1 and 5. The following visits are the visits of safety and PK, PD and immunogenicity and also preliminary effectiveness). Patients will also receive background treatment Methotrexate+ Folic acid.

    Drug: MabThera®

Interventions

  • Rituximab 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)

  • MabThera® 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)

06

What researchers measure

Primary outcomes

  1. AUC(w2-24)

    Area Under the Concentration Time Curve predose Day 1 to Week 24 (AUC(w2-24).

    Time frame: Day 1 to Week 24

  2. AUC0-inf

    Area Under the Concentration Time Curve extrapolated from 0 to infinity (AUC0-inf)

    Time frame: Day 1 to Week 24

  3. Cmax

    Maximum Plasma Concentration (Cmax) after Dose 2

    Time frame: Dose 2 to the end of the study or Week 24

Secondary outcomes

  1. Ctrough

    Residual concentration (Ctrough) before the second infusion on Day 15

    Time frame: Day 1 to Day 15

  2. AUC0-d15

    Area under the concentration-time curve from 0 (directly pre-infusion on Day 1) before pre-infusion measurement on Day 15 (AUC0-d15)

    Time frame: Day 1 - Day 15 (before infusion)

  3. AUC0-w12

    Area under the concentration-time curve from 0 and before measurement at Week 12 (AUC0-w12)

    Time frame: Day 1 - Week 12 (before infusion)

  4. AUCd15-n24

    Area under the concentration-time curve from measurement immediately before the second infusion (Day 15) before measuring in point Week 24 (AUCd15-n24)

    Time frame: Day 15 - Week 24

07

Study locations

12 sites
  • Immanuel Kant Baltic Federal University
    Kaliningrad, Russian Federation
  • Scientific-Research Medical Complex Your Health
    Kazan, Russian Federation
  • LLC "Medical Center Revma-Med"
    Kemerovo, Russian Federation
  • LLC "Korolev Family Clinic №4"
    Korolev, Russian Federation
  • Moscow City Clinical Hospital №1
    Moscow, Russian Federation
  • V.A. Nasonova Research Institute of Rheumatology
    Moscow, Russian Federation
  • Orenburg State Medical University
    Orenburg, Russian Federation
  • JSC "Northwestern Center for Evidence-Based Medicine"
    Saint-Petersburg, Russian Federation
  • LLC "Interleukin"
    Saint-Petersburg, Russian Federation
  • Medical center "Capital-Polis"
    Saint-Petersburg, Russian Federation
  • Saratov State Medical University
    Saratov, Russian Federation
  • LLC "Biomed"
    Vladimir, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Nov 2024, 17 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 17 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2023
First posted
Dec 18, 2023
StartActual
Jun 14, 2023
Primary completionEst.
Nov 2024
CompletionEst.
Apr 2025
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06175338
Lead sponsor
Mabscale, LLC
Responsible party
Sponsor
First posted
Dec 18, 2023
Start date
Jun 14, 2023
Primary completion
Nov 2024 (estimated)
Completion
Apr 2025 (estimated)
Last update
Sep 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion